AbbVie Inc (ABBV)vsModerna Inc (MRNA)
ABBV
AbbVie Inc
$257.60
-2.24%
HEALTHCARE · Cap: $447.53B
MRNA
Moderna Inc
$54.49
-2.36%
HEALTHCARE · Cap: $24.53B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2723% more annual revenue ($62.82B vs $2.23B). ABBV leads profitability with a 5.8% profit margin vs -143.5%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
MRNA
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.8%
Fair Value
$147.26
Current Price
$257.60
$110.34 premium
Margin of Safety
+70.5%
Fair Value
$137.40
Current Price
$54.49
$82.91 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Revenue surging 260.2% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Weak financial health signals
ROE of -43.1% — below average capital efficiency
Earnings declined 85.1%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.42 suggests the stock is reasonably priced for its growth.
Bull Case : MRNA
The strongest argument for MRNA centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 260.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 124.8x leaves little room for execution misses.
Bear Case : MRNA
The primary concerns for MRNA are Piotroski F-Score, Return on Equity, EPS Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while MRNA is a hypergrowth play — different risk/reward profiles.
MRNA carries more volatility with a beta of 0.94 — expect wider price swings.
MRNA is growing revenue faster at 260.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 32/100) and 12.4% revenue growth. MRNA offers better value entry with a 70.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?